ROS1 and non-small cell lung carcinoma: Although the prevalence of ROS1-rearrangement was higher in East Asia and the therapy regimens were limited in China, the results of this Chinese multicentre observational study showed that the presence of ROS1 rearranged in NSCLC may increase the risk of TEEs.